PTEIQ vs. AEON, SXTP, KTTA, ADIL, DRMA, ATNF, ADXS, TCRT, ALZN, and KLTO
Should you be buying PolarityTE stock or one of its competitors? The main competitors of PolarityTE include AEON Biopharma (AEON), 60 Degrees Pharmaceuticals (SXTP), Pasithea Therapeutics (KTTA), Adial Pharmaceuticals (ADIL), Dermata Therapeutics (DRMA), 180 Life Sciences (ATNF), Ayala Pharmaceuticals (ADXS), Alaunos Therapeutics (TCRT), Alzamend Neuro (ALZN), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry.
PolarityTE vs.
AEON Biopharma (NASDAQ:AEON) and PolarityTE (NASDAQ:PTEIQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
AEON Biopharma received 8 more outperform votes than PolarityTE when rated by MarketBeat users.
AEON Biopharma's return on equity of 0.00% beat PolarityTE's return on equity.
PolarityTE has higher revenue and earnings than AEON Biopharma. PolarityTE is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 11.8% of PolarityTE shares are held by institutional investors. 7.0% of AEON Biopharma shares are held by company insiders. Comparatively, 5.4% of PolarityTE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, AEON Biopharma had 5 more articles in the media than PolarityTE. MarketBeat recorded 5 mentions for AEON Biopharma and 0 mentions for PolarityTE. PolarityTE's average media sentiment score of 0.00 beat AEON Biopharma's score of -0.36 indicating that PolarityTE is being referred to more favorably in the news media.
AEON Biopharma currently has a consensus target price of $360.00, suggesting a potential upside of 83,543.12%. Given AEON Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe AEON Biopharma is more favorable than PolarityTE.
AEON Biopharma has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, PolarityTE has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Summary
AEON Biopharma beats PolarityTE on 10 of the 15 factors compared between the two stocks.
Get PolarityTE News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTEIQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTEIQ vs. The Competition
PolarityTE Competitors List
Related Companies and Tools
This page (NASDAQ:PTEIQ) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy PTEIQ Stock Free PTEIQ Stock Alerts